LIFESTAR®

Vascular Stent System



FDA APPROVED for the **Treatment of Iliac Occlusive Disease***

Simply Brilliant

Highly Visible Stent System

Optimized Pin-and-Pull Delivery System for **Simple Deployments**

Designed for Easy, **Precise Placement**

*See back for complete indication.

BARD | PERIPHERAL VASCULAR

LIFESTAR®
Vascular Stent System

LIFESTAR® Vascular Stent System Ordering Information

Stent Diameter (mm)	Catheter Length (cm)	Stent Length (mm)	Product Code
7	80	20	VIES07020
		30	VIES07030
		40	VIES07040
		60	VIES07060
		80	VIES07080
		100	VIES07100
8	80	20	VIES08020
		30	VIES08030
		40	VIES08040
		60	VIES08060
		80	VIES08080
		100	VIES08100
9	80	20	VIES09020
		30	VIES09030
		40	VIES09040
		60	VIES09060
		80	VIES09080
		100	VIES09100
10	80	20	VIES10020
		30	VIES10030
		40	VIES10040
		60	VIES10060
		80	VIES10080
		100	VIES10100



LIFESTAR® Vascular Stent System

Indications: The BARD® LIFESTAR® Vascular Stent System is indicated for the treatment of: • Iliac occlusive disease in patients with symptomatic vascular disease of the common and/or external iliac arteries • Residual stenoses with impaired perfusion (pressure gradient) following balloon dilatation, especially in stages III and IV according to Fontaine • Dissection • Detached arteriosclerotic plaque material and luminal obstruction following balloon dilatation • Occlusion after thrombolysis or after aspiration and before dilatation • Restenosis or reocclusion

Contraindications: Contraindications for the BARD® LIFESTAR® Vascular Stent System include, but may not be limited to: • Uncorrected coagulopathies • Functionally relevant obstruction of the inflow path, poor outflow or no distal runoff • Fresh, soft thrombotic or embolic material • Placement in the distal superficial femoral artery • Placement in the popliteal artery

Warnings: Should unusual resistance be felt at any time during the procedure, the entire system (introducer sheath or guiding catheter and stent delivery system) should be removed as a single unit. • Patients with known hypersensitivity to nickel-titanium may suffer an allergic reaction to this implant. • Stenting across a major bifurcation may hinder or prevent future diagnostic or therapeutic procedures. • Overstretching the artery may result in spasm, dissection, and/or perforation that may result in serious complications.

Precautions: This device is intended for use only by physicians who are familiar with the principles, clinical applications, complications, side effects, and risks commonly associated with vascular stenting. It is strongly recommended that physician operators adhere to all applicable institutional, local, state, and federal guidelines and protocols regarding adequate procedural training.

Potential Complications: Potential adverse events associated with the use of the BARD® LIFESTAR® Vascular Stent System include, but may not be limited to the usual complications reported for vascular procedures such as: • Adverse and / or allergic reactions to antiplatelet agents / contrast medium / drugs / implant material • Aneurysm • Arrhythmia • Arterial occlusion / thrombosis at puncture site or remote site • Arteriovenous fistula • Bacteremia or septicemia • Bleeding from anticoagulant or antiplatelet medications • Detachment of a component of the system • Embolization, distal (air, tissue or thrombotic emboli) • Emergent surgery to remove stent • Fever • Groin hematoma, with or without surgical repair • Hemorrhage, with or without transfusion • Hyperperfusion syndrome • Hypotension / hypertension • Infection and pain at insertion site • Ischemia / infarction of tissue / organ • Pseudoaneurysm • Restenosis, recurrent narrowing or occlusion of stented segment • Stent embolization • Stent fracture • Stent malposition (failure to deliver the stent to the intended site) • Stent migration • Stent thrombosis / occlusion • Vasospasm • Vessel spasm or recoil • Vessel tear, dissection, perforation, or rupture • Vessel total occlusion

AUSTRIA	Bard Medica S.A., MGC-Top Nr. D36, 3.OG Ebene, Modecenterstraße 22, A - 1030 Wien, Austria. Tel: +43-1-49-49-130 Fax: +43-1-49-49-130-30
BENELUX	Bard Benelux n.v., Hagelberg 2, 2250 Olen, Belgium. Tel: +32 14 286950 Fax: +32 14 286966
CZECH REPUBLIC	Bard Czech Republic s.r.o., Taborska 619, 140 00 Prague, Czech Republic. Tel: +420 242 408630 Fax: +420 242 410 185
FRANCE	Bard France SAS, Av. Joseph Kessel 164-166, Parkile P14, 78960 Voisins-le-Bretonneux, France. Tel: +33 1 39305858 Fax: +33 1 39305859
GERMANY	C. R. Bard GmbH, Wachhausstrasse 6, 76227 Karlsruhe, Germany. Tel: +49 721 94450 Fax: +49 721 9445111
GREECE	Bard Hellas SA, 22, Alkiviadou St & 72, Vouliagmenis Av, 16675 Glyfada, Greece. Tel: +30 210 9690770 Fax: +30 210 9628810
IRELAND	Bard Limited., Arena House, Arena Road, Sandyford, Dublin 18, Ireland. Tel: +353 121 30706 Fax: +353 121 30604
ITALY	Bard S.p.A., Via Cina 444, 00144 Roma, Italy. Tel: +39 06 524931 Fax: +39 06 5295852
NETHERLANDS	C. R. Bard Netherlands Sales B.V., Lorentzlaan 4, 3401 MX IJsselstein, The Netherlands. Tel: +31 (0)88 01 22 500 Fax: +31 (0)88 01 22 501
NORDIC	Bard Norden AB, Karbingatan 22, 254 67 Helsingborg, Sweden. Tel: +46 42 386000 Fax: +46 42 386010
POLAND	Bard Poland sp. z o.o., ul. Cybernetyki 7b, 02-677 Warszawa, Poland. Tel: +48 22 3210930 Fax: +48 22 3210938
SPAIN	Bard de España S.A.U., Plaza Europa 41-43, 5a Planta, (Torre Realia), 08908 L'Hospitalet de Llobregat, Barcelona, Spain. Tel: +34 93 2537800 Fax: +34 93 205 82 00
SWITZERLAND	Bard Medica SA, Seestrasse 64, 8942 Oberrieden/Zürich, Switzerland. Tel: +41 44 7225360 Fax: +41 44 7225370
UK	Bard Limited, Forest House, Tilgate Forest Business Park, Brighton Road, Crawley, West Sussex RH11 9BP, UK. Tel: +44 1293 529555 Fax: +44 1293 552428

Please consult product labels and package inserts for indications, contraindications, hazards, warnings, cautions and instructions for use.

BARD | PERIPHERAL VASCULAR